2 results
Categories
Human Remove Human filter
-
List item
Orphan designation: Obinutuzumab for: Treatment of follicular lymphoma
Date of first decision: 19/06/2015, Positive, Last updated: 21/02/2018The medicines bendamustine, ibritumomab tiuxetan, interferon alfa 2b and rituximab … The medicines bendamustine, ibritumomab … EMA/COMP/346519/2015 Page 2/4 tiuxetan, interferon alfa 2b and rituximab … -
List item
Human medicine European public assessment report (EPAR): Gazyvaro
Obinutuzumab, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 22/07/2014,,
, Revision: 11, Authorised, Last updated: 29/01/2021